60 Degrees Pharmaceuticals (NASDAQ:SXTP) Rating Lowered to Sell at Wall Street Zen

60 Degrees Pharmaceuticals (NASDAQ:SXTP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also issued reports on SXTP. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Wednesday, June 11th. HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 28th. Finally, Ascendiant Capital Markets raised their price target on shares of 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the company a “buy” rating in a research note on Monday, June 2nd.

60 Degrees Pharmaceuticals Stock Down 3.1%

NASDAQ SXTP opened at $2.21 on Friday. The company has a market cap of $3.26 million, a price-to-earnings ratio of -0.22 and a beta of 2.88. 60 Degrees Pharmaceuticals has a twelve month low of $1.41 and a twelve month high of $35.99. The business’s fifty day moving average is $2.63 and its 200 day moving average is $3.52.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its earnings results on Thursday, May 15th. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.31) by ($0.25). The business had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.15 million. On average, research analysts anticipate that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.